New Drugs Approved

FDA Approves Sohonos for Fibrodysplasia Ossificans Progressiva on August 16, 2023

FDA Approves Sohonos for Fibrodysplasia Ossificans Progressiva on August 16, 2023

What is Sohonos prescribed for?   Sohonos is prescribed to reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva. What is the name of the drug and what does it do? Sohonos, pronounced so-ho-nos, (generic name:...

FDA Approves Izervay for Treating Severe  Age-related Macular Degeneration August 4, 2023

FDA Approves Izervay for Treating Severe  Age-related Macular Degeneration August 4, 2023

What is Izervay prescribed for?   Izervay is prescribed to treat geographic atrophy (GA) secondary to age-related macular degeneration. What is the name of the drug and what does it do? Izervay, pronounced  EYE-ZER-VEY, (generic name: avacincaptad pegol) is a prescription medication approved for the treatment of geographic atrophy (GA), which is a...

FDA Approves XDEMVY for Treating Demodex Blepharitis on July 25, 2023

FDA Approves XDEMVY for Treating Demodex Blepharitis on July 25, 2023

What is XDEMVY prescribed for?   XDEMVY is prescribed to treat a parasitic infection of the eye (Demodex blepharitis) that can  especially affect the eyelids. What is the name of the drug and what does it do? XDEMVY, pronounced X-DEM-VEE, (generic name: lotilaner)  is a prescription medication approved for the treatment of Demodex blepharitis, a...

FDA Approves Leqembi for Alzheimer’s Disease on on July 6, 2023

FDA Approves Leqembi for Alzheimer’s Disease on on July 6, 2023

What is Leqembi prescribed for?   Leqembi is prescribed to treat Alzheimer’s disease for people in the early stages of the disease. What is the name of the drug and what does it do?  The U.S. Food and Drug Administration has approved Leqembi (generic name: lecanemab-irmb), pronounced “leh-kem’-bee,” for the treatment of Alzheimer's disease. ...

FDA Approves Dupixent for Children Suffering from Eosinophilic Esophagitis on January 2024

FDA Approves Dupixent for Children Suffering from Eosinophilic Esophagitis on January 2024

What is Dupixent prescribed for? DUPIXENT (generic name: dupilumab), pronounced DU-pix-ent is prescribed for children aged 1 year and older to treat eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. EoE is caused by a buildup of eosinophils, a type of white blood cell, which leads to damage and inflammation in the esophagus. This can...

FDA Approves Amtagvi for Advanced Skin Cancer on February 16, 2024

FDA Approves Amtagvi for Advanced Skin Cancer on February 16, 2024

What is Amtagvi prescribed for?   Amtagvi is prescribed to treat adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. What is the name of the drug and what does it do?  The newly approved drug is called Amtagvi...